(BAYN) Bayer NA - Ratings and Ratios
Exchange: XETRA • Country: Germany • Currency: EUR • Type: Common Stock • ISIN: DE000BAY0017
BAYN: Pharmaceuticals, Consumer, Health, Agricultural, Products
Bayer Aktiengesellschaft is a global life science company with a diversified portfolio addressing key areas of healthcare and agriculture. The company operates through three core segments: Pharmaceuticals, Consumer Health, and Crop Science. The Pharmaceuticals segment focuses on innovative treatments for cardiology, womens health, oncology, hematology, and ophthalmology, including cell and gene therapies. The Consumer Health segment offers a broad range of over-the-counter medications, skincare products, and dietary supplements. The Crop Science segment provides agricultural solutions, including crop protection chemicals, seeds, and digital farming tools.
The company has established strategic collaborations with leading research institutions and biotech firms, including MD Anderson Cancer Center, Dewpoint Therapeutics, and Evotec AG, to advance its pipeline in oncology, cardiovascular, and gynecological diseases. Its distribution network spans wholesalers, pharmacies, supermarkets, online retailers, and direct sales to farmers. Founded in 1863, Bayer is headquartered in Leverkusen, Germany, and is one of the largest and most established players in the life sciences industry.
Additional Sources for BAYN Stock
BAYN Stock Overview
| Market Cap in USD | 24,648m |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| GiC Sub-Industry | Pharmaceuticals |
| IPO / Inception |
BAYN Stock Ratings
| Growth Rating | -67.3 |
| Fundamental | -11.7 |
| Dividend Rating | 0.48 |
| Rel. Strength | -14.4 |
| Analysts | - |
| Fair Price Momentum | 19.48 EUR |
| Fair Price DCF | 90.63 EUR |
BAYN Dividends
| Dividend Yield 12m | 0.91% |
| Yield on Cost 5y | 0.41% |
| Annual Growth 5y | -47.66% |
| Payout Consistency | 85.9% |
BAYN Growth Ratios
| Growth Correlation 3m | -1% |
| Growth Correlation 12m | -72.8% |
| Growth Correlation 5y | -55.9% |
| CAGR 5y | -15.34% |
| CAGR/Max DD 5y | -0.22 |
| Sharpe Ratio 12m | -0.05 |
| Alpha | -23.39 |
| Beta | 0.496 |
| Volatility | 31.69% |
| Current Volume | 3782.2k |
| Average Volume 20d | 3611.6k |
As of April 26, 2025, the stock is trading at EUR 22.99 with a total of 3,782,168 shares traded.
Over the past week, the price has changed by +7.00%, over one month by -2.46%, over three months by +7.20% and over the past year by -14.17%.
Neither. Based on ValueRay Fundamental Analyses, Bayer NA is currently (April 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -11.70 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BAYN as of April 2025 is 19.48. This means that BAYN is currently overvalued and has a potential downside of -15.27%.
Bayer NA has no consensus analysts rating.
According to ValueRays Forecast Model, BAYN Bayer NA will be worth about 21 in April 2026. The stock is currently trading at 22.99. This means that the stock has a potential downside of -8.53%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 27.5 | 19.7% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 21 | -8.5% |